Adaptive Biotechnologies (ADPT) Director Peter M. Neupert Sells Shares

What Happened
Peter M. Neupert, a director of Adaptive Biotechnologies Corp (ADPT), exercised options to acquire 15,000 shares at $6.32 (cost $94,800) on August 17, 2026 and sold a total of 124,690 shares in open-market transactions the same day. The three sale tranches generated aggregate proceeds of approximately $3,135,850 (15,000 shares at $25.23; 40,000 at $25.10; 69,690 at $25.16). The filing also reports a derivative disposition of 15,000 shares at $0 (see footnote on option vesting).

Key Details

• Transaction date: 2026-08-17; Form 4 filed 2026-08-19 (timely filing). Accession: 0001237566-26-000003.
• Sales: 15,000 shares @ weighted avg $25.23 (range $25.21–$25.27), 40,000 @ $25.10 (range $25.06–$25.17), 69,690 @ $25.16 (range $25.14–$25.22). Total sale proceeds ≈ $3,135,850.
• Exercise: 15,000 shares acquired by exercise @ $6.32 (total cost $94,800).
• Additional derivative line: 15,000 shares reported as a disposition at $0; footnote F4 notes the option was fully vested and would have expired Oct 18, 2026.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes F1–F3 explain reported sale prices are weighted averages of multiple trades within the given price ranges.

Context
This was an option exercise followed by open-market sales (a common practice when insiders exercise vested options and immediately sell some or all shares). The filings show weighted-average sale prices and ranges; the presence of a $0 derivative disposition should be interpreted by reviewing the full Form 4 (it may reflect option mechanics or net settlement). These are factual disclosures — they document transactions but do not by themselves explain the insider's motives.